bluebird bio, Inc. (BLUE)
After hours:
| Previous Close | 1.1200 |
| Open | 1.1400 |
| Bid | 1.0400 x 5600 |
| Ask | 1.0700 x 5600 |
| Day's Range | 1.0200 - 1.1600 |
| 52 Week Range | 0.8500 - 5.5300 |
| Volume | |
| Avg. Volume | 8,331,537 |
| Market Cap | 216.835M |
| Beta (5Y Monthly) | 0.87 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
bluebird bio Reports First Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
SOMERVILLE, Mass., May 09, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported first quarter results and business highlights for the quarter ended March 31, 2024, including recent commercial and operational progress.
- Business Wire
bluebird bio Announces First Quarter 2024 Results Call Date and Upcoming Investor Events
SOMERVILLE, Mass., May 06, 2024--bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss first quarter 2024 results and business updates on May 9, at 8:00 a.m. ET.
- Business Wire
bluebird bio Announces Completion of First Cell Collection for LYFGENIA™ Gene Therapy
SOMERVILLE, Mass., May 06, 2024--bluebird bio, Inc. (Nasdaq: BLUE) announced today that it has completed the first commercial cell collection for LYFGENIA (lovotibeglogene autotemcel), a one-time gene therapy for the treatment of sickle cell disease in patients with a history of vaso-occlusive events. LYFGENIA was approved by the FDA in December 2023 and is the most deeply studied gene therapy for sickle cell disease, with the longest follow-up in the field.
